Projects (72)

BICS: A randomised, double-blind placebo controlled trial of the effectiveness of the beta-blocker bisoprolol in preventing exacerbations of chronic obstructive pulmonary disease Jun 1, 2017 - May 31, 2022

RELIEF: A Randomised, Double-blind, Placebo-Controlled, Crossover, Dose Escalation Study of BLU-5937 in subjects with Unexplained or Refractory Chronic Cough Jun 1, 2020 - Dec 31, 2020

ISABELA1: A Phase 3, randomized, double-blind, parallel-group, placebocontrolled multicenter study to evaluate the efficacy and safety of two doses of GLPG1690 in addition to local standard of care for minimum 52 weeks in subjects with idiopathic pulmonary fibrosis. Aug 1, 2019 - Dec 31, 2022

SCENIC: Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study with Inhaled RVT-1601 for the Treatment of Persistent Cough in Patients with Idiopathic Pulmonary Fibrosis (IPF) May 1, 2019 - Jan 31, 2022

ATLAS: A Randomized Open-Label, Phase 1b Study of the Safety of Pirfenidone Solution for Inhalation (AP01) in Patients with Idiopathic Pulmonary Fibrosis Jun 1, 2019 - Jan 31, 2022

TR12: A Phase 2, Double-blind, Randomized, Placebo-controlled, Two-Treatment, Two-Period Crossover Efficacy and Safety Study in Idiopathic Pulmonary Fibrosis with Nalbuphine ER Tablets for the Treatment of Cough Oct 1, 2019 - Dec 31, 2022

An exploratory sub-study to protocol GLPG1690-CL-303 to assess lung function in patients with idiopathic pulmonary fibrosis, using hyperpolarized xenon magnetic resonance imaging Nov 1, 2019 - Apr 30, 2022

CageTag: Caged Theranostics as a Universal Platform for Nuclear Medicine Apr 1, 2022 - Mar 31, 2025
Molecular imaging in cancer allows specific features of the disease to be characterised. In particular, receptor expression levels can be prognostic and allow targeting of systemic radiotherapies. There are roadblocks in the widespread use of molecul... Read More about CageTag: Caged Theranostics as a Universal Platform for Nuclear Medicine.

Development and publication of the booklet for the pulmonary fibrosis (disease with a degree of similarity to coronavirus disease). Nov 1, 2020 - Oct 31, 2021
Chronic diseases associated with fibrosis present a challenge for healthcare; two of them are idiopathic pulmonary fibrosis (IPF) and lymphoedema. IPF is a form of lung disease in which scarring occurs (with no known cause) leading to increased breat... Read More about Development and publication of the booklet for the pulmonary fibrosis (disease with a degree of similarity to coronavirus disease)..

Randomised, double-blind, parallel group. Phase 2b dose-finding, efficacy and safety study of 12-week twice daily oral administration of BAY 1817080 compared to placebo in the treatment of refractory and/or unexplained chronic cough (RUCC) Jan 1, 2021 - Feb 28, 2022

Consumables for PhD project Study of Tumour Regulatory Molecules as Markers of Malignancy in Pancreatic Cystic Lesions (TEM-PAC) Feb 1, 2021 - Jul 31, 2026

Molecular pathways of pancreatic cancer carcinogenesis from pancreatic cystic neoplasms to adenocarcinoma Sep 1, 2020 - Aug 31, 2023
Pancreatic cancer is one of the main research areas of expertise of Professor Maraveyas and his team. This is an exciting opportunity to work on molecular pathways in pancreatic tissue that reflect the early changes during carcinogenesis and transla... Read More about Molecular pathways of pancreatic cancer carcinogenesis from pancreatic cystic neoplasms to adenocarcinoma.

SERENITY: Towards cancer patient empowerment for optimal use of antithrombotic therapy at the end of life Oct 1, 2022 - Sep 30, 2027

Phase 2a, Randomised, Double-Blind, Placebo-Controlled, Two-Part Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetic Profiles of Inhaled Doses of NOC-100 in Adult Participants with Chronic or Acute Cough Nov 1, 2021 - Dec 31, 2023

CRN funding Sep 1, 2021 - Mar 31, 2022

EARLY DIAPAC: EARLY DIAgnosis of PAncreatic Cancer by combined proteomics and genomics testing of pancreatic cyst fluid. Dec 1, 2022 - Aug 31, 2024
This is part of a total project cost of £98,508.70.

Updating (Reviewing and Printing) the Patient's Guide to Pulmonary Fibrosis. Nov 1, 2022 - Oct 31, 2023
This is an annual follow up/annual review for the Project 3632727: Development And Publication Of The Booklet For The Pulmonary Fibrosis (disease With A Degree Of Similarity To Coronavirus Disease).


Chronic diseases associated... Read More about Updating (Reviewing and Printing) the Patient's Guide to Pulmonary Fibrosis..

A cell model for discovering biomarkers and druggable targets for pulmonary fibrosis May 1, 2023 - Nov 30, 2024

Quantitative proteomic analysis of pancreatic cyst fluid for early detection of cancer using University of Hull HPC Viper Apr 1, 2022 - Feb 28, 2023
The timely diagnosis of pancreatic ductal adenocarcinoma (PDAC) is challenging due to a lack of disease-specific symptoms, resulting in the majority of patients presenting with advanced disease and poor prognosis. Detection of PDAC, ideally at a prem... Read More about Quantitative proteomic analysis of pancreatic cyst fluid for early detection of cancer using University of Hull HPC Viper.

PreclinHUPET2: Enabling Enhanced Preclinical Nuclear Imaging For The North Of England Feb 1, 2023 - Jan 31, 2024
The grant application is to upgrade the preclinical scanning facilities for nuclear imaging of small animals (mice and rats) at the University of Hull. These facilities are used for research into disease and human health. The main areas that will be... Read More about PreclinHUPET2: Enabling Enhanced Preclinical Nuclear Imaging For The North Of England.